Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events

Toshiaki Ohkuma, Sanne A. E. Peters, Mark Woodward

Diabetologia · 2018 · Meta-analysis

doi:10.1007/s00125-018-4664-5

Abstract

Aims/hypothesis. Diabetes has been shown to be a risk factor for some cancers. Whether diabetes confers the same excess risk of cancer, overall and by site, in women and men is unknown.

Methods. A systematic search was performed in PubMed for cohort studies published up to December 2016. Selected studies reported sex-specific relative risk (RR) estimates for the association between diabetes and cancer adjusted at least for age in both sexes. Random-effects meta-analyses with inverse-variance weighting were used to obtain pooled sex-specific RRs and women-to-men ratios of RRs (RRRs) for all-site and site-specific cancers.

Results. Data on all-site cancer events (incident or fatal only) were available from 121 cohorts (19,239,302 individuals; 1,082,592 events). The pooled adjusted RR for all-site cancer associated with diabetes was 1.27 (95% CI 1.21, 1.32) in women and 1.19 (1.13, 1.25) in men. Women with diabetes had ~6% greater risk compared with men with diabetes (the pooled RRR was 1.06, 95% CI 1.03, 1.09). Corresponding pooled RRRs were 1.10 (1.07, 1.13) for all-site cancer incidence and 1.03 (0.99, 1.06) for all-site cancer mortality. Diabetes also conferred a significantly greater RR in women than men for oral, stomach and kidney cancer, and for leukaemia, but a lower RR for liver cancer.

Conclusions/interpretation. Diabetes is a risk factor for all-site cancer for both women and men, but the excess risk of cancer associated with diabetes is slightly greater for women than men. The direction and magnitude of sex differences varies by location of the cancer.

Electronic supplementary material. The online version of this article (10.1007/s00125-018-4664-5) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Cancer is the second leading causes of death in the world. In 2015, there were 17.5 million incident cancer cases and 8.7 million cancer deaths globally, and it is estimated that one in four women and one in three men develop cancer during their lifetime. The incidence of cancer is expected to increase in the next decades, emphasising the importance of efficient prevention and treatment of cancer worldwide.

The prevalence of diabetes has also grown rapidly. In 2015, one in 11 adults (415 million) were reported to have diabetes, five million deaths were attributed to diabetes, and 12% of global health expenditure was spent on diabetes and its complications. Diabetes has been associated with the risk of all-site and some site-specific cancers in several systematic reviews and meta-analyses. However, only a minority of these associations are based on robust supporting evidence without question of significant bias. To date, there has been no systematic overview of the evidence available on sex differences in the association between diabetes and cancer. We have previously published compelling evidence that women with diabetes are at an increased risk of stroke, coronary heart disease and dementia compared with their male peers. We now question whether this is also true for cancer. In this study, we conducted the most comprehensive systematic review and meta-analysis, to date, to estimate the relative effect of diabetes on the risk of cancer in women compared with men.

Search strategy and selection criteria

A systematic search was performed in PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) on 23 December 2016 using a combined text word and medical subject heading search strategy (electronic supplementary material [ESM] Table 1). The reference lists of identified reports were also checked for other potentially relevant studies.

Observational cohort studies in general populations were included if they had provided relative risks (RRs), or equivalents, for the association between diabetes and cancer in both women and men. Studies were excluded if they had not adjusted at least for age or did not provide information about the variability around the point estimate, or if they only had data for one sex. In case of duplicate reports from the same study, the study providing the longest follow-up or the highest number of cases was included. We also used individual participant data from the Asia Pacific Cohort Studies Collaboration (APCSC), treated as two separate combinations of data from cohorts in Asia and cohorts from Australia or New Zealand, as in our previous work. One author (TO) did the search and extracted the data. Uncertainties regarding the inclusion or exclusion of articles and data extraction were discussed by all authors and resolved by mutual consent. The meta-analysis was done in accordance with the PRISMA criteria.

Data extraction and statistical analysis

The primary endpoint was all-site cancer events (incident or, if this was all that was presented, mortal only). The secondary endpoints were all-site cancer incidence (i.e. omitting studies that only reported mortality), all-site cancer mortality and, for those cancers that could present in both sexes, site-specific cancer events, site-specific incidence and site-specific mortality. In sensitivity analysis we also compared all-site cancer incidence and mortality when restricting to the studies that reported both.

The primary metrics were the pooled adjusted RRs and the women-to-men ratios of RRs (RRRs) for individuals with diabetes vs those without diabetes. For each study, we extracted the sex-specific RRs and 95% CIs for individuals with diabetes vs those without diabetes, from which we estimated the RRRs and 95% CIs. To include the largest set of individuals and cancer endpoints, studies that reported either age-adjusted or multiple-adjusted (maximum-available-adjusted, i.e. the maximum set of adjustments available for each study) results were included in our primary analyses. In pooling multiple-adjusted results, the set of adjustments made were allowed to vary by study, but had to include at least one other risk factor for cancer, in addition to age. We obtained pooled estimates of sex-specific RRs across studies using random-effects meta-analyses applied on the loge scale. Individual studies were weighted according to the inverse variance of loge RRs. The same method was used to pool the RRRs.

The I2 statistic was used to estimate the percentage of variability across studies due to between-study heterogeneity and the Q test was used to assess whether there was a significant lack of homogeneity. The possibility of publication bias was explored using funnel plots and Egger’s and Begg’s tests. Random-effects meta-regression analyses were used to test for differences between pre-assigned subgroups: study region (Asia or Non-Asia), year of baseline study (pre-1985 or 1986 onwards, and also examined as a continuous variable), ascertainment of diabetes (self-reported only or others), type of diabetes (type 1 or type 2, where studies which did not differentiate type were classified as type 2), level of adjustment (age-adjusted or multiple-adjusted), and study quality (the Newcastle–Ottawa Scale [ESM Table 2], ≥7 or <7 points, and also examined as a continuous variable). Post hoc, we also considered absolute risk difference, examined as a categorical and continuous variable) (ESM Table 3). A p value of below 0.05 was considered to be statistically significant in analyses for the primary analyses, i.e. all-site cancer. As many statistical tests were envisaged, a p value of below 0.01 was taken to denote significance for site-specific cancers. All analyses were performed using Stata software (release 13; StataCorp, College Station, TX, USA).

Results

Of the 6371 articles identified through the systematic search, 371 articles qualified for full-text evaluation, and 107 articles provided summary data on the association between diabetes and the risk of cancer for both sexes. In addition, 36 cohorts with individual participant data from the APCSC were included (Fig. 1).

Characteristics of the studies that reported the association between diabetes and all-site cancer incidence or mortality are shown in Table 1 and ESM Table 4. Data on all-site cancer were available from 47 studies, involving 121 cohorts, 19,239,302 individuals (not counting one study that did not state the total number of participants), and 1,082,592 events (not counting one study that did not state the total number of cancer events).

The maximum-available-adjusted pooled sex-specific RR estimates for combined fatal and non-fatal cancer associated with diabetes were 1.27 (95% CI 1.21, 1.32, p < 0.001) for women and 1.19 (1.13, 1.25, p < 0.001) for men (Fig. 2). The pooled women-to-men RRR was 1.06 (1.03, 1.09, p < 0.001, Fig. 3). The I2 statistic for heterogeneity between studies was 66.7%, with no evidence of publication bias (Egger’s test p = 0.13, Begg’s test p = 0.16, ESM Fig. 1). The corresponding RRR was 1.06 (1.02, 1.11, p = 0.005) for type 1 diabetes and 1.06 (1.03, 1.09, p < 0.001) for type 2 diabetes, without evidence of significant heterogeneity by type of diabetes (p for interaction = 0.88, Fig. 4). Exclusion of 22 studies that provided only age-adjusted results had no appreciable effect on the pooled RR estimates (multiple-adjusted pooled RR in women 1.25 [1.17, 1.34], p < 0.001, RR in men 1.20 [1.11, 1.29], p < 0.001, RRR 1.06 [1.03, 1.10], p < 0.001, I2 = 48.9%) (ESM Figs 2 and 3).

The pooled RRR did not vary substantially by study region (p = 0.45), year of baseline study (p = 0.54 for categorical analysis, p = 0.18 for continuous analysis), ascertainment of diabetes (p = 0.72), level of adjustment (p = 0.70), quality of study (p = 0.09 for categorical analysis) or absolute risk difference between men and women (p = 0.82 for categorical analysis, p = 0.99 for continuous analysis), with the exception of continuous analysis for quality of study, p = 0.01) (Fig. 4 and ESM Fig. 4).

Secondary analyses of incidence (fatal or not) and mortality alone for all-site cancer are described in the ESM. The pooled women-to-men RRR for incidence was 1.10 (1.07, 1.13, p < 0.001) (ESM Fig. 5) and for mortality was 1.03 (0.99, 1.06, p = 0.16) (ESM Fig. 6).

In sensitivity analysis using only those studies which provided the RRs for both incidence and mortality, the pooled maximum-available-adjusted RRR was 1.12 (1.06, 1.17, p < 0.001) for all-site cancer incidence, and 1.10 (1.00, 1.21, p = 0.04) for all-site cancer mortality (ESM Fig. 7).

Data on site-specific cancer were available for 50 sites (50 sites for incidence and 29 sites for mortality) (https://www.georgeinstitute.org/sites/default/files/esm-table.pdf). Diabetes was associated with an increased risk of cancer in 43 sites in women and 42 sites in men, with a statistically significant increase (p < 0.01) in risk for those with diabetes in 20 sites in women and 18 sites in men (ESM Fig. 8). The pooled maximum-available-adjusted RRR was statistically significantly higher in women than men for kidney (1.11 [99% CI 1.04, 1.18], p < 0.001), oral (1.13 [1.00, 1.28], p = 0.009), stomach cancer (1.14 [1.07, 1.22], p < 0.001) and leukaemia (1.15 [1.02, 1.28], p = 0.002), whereas it was statistically significantly lower for liver cancer (0.88 [0.79, 0.99], p = 0.005) (Fig. 5). Separate results for incidence and mortality by site of cancer are described in the ESM (ESM Figs 5, 6, 9–24).

Discussion

This systematic review, with meta-analysis, of 121 cohorts including more than 19 million individuals and over one million all-site cancer events, demonstrated that diabetes was associated with a 6% higher excess risk of all-site cancer in women than men. Diabetes was associated with several site-specific cancers and conferred a significantly greater excess risk in women than men for oral, stomach and kidney cancer and for leukaemia, but a lower excess risk for liver cancer. The findings were broadly consistent for incident and fatal cancers and across a wide range of prespecified subgroups.

Our findings are in agreement with a previous meta-analysis, which found that the risk of all-site cancer incidence and mortality was significantly increased in both sexes. However, this previous meta-analysis was about a tenth of the size of the current study, and included single-sex studies, and therefore was not able to reliably quantify sex differences as they could have been explained by differences in methods, confounders adjusted for, and the background risks between studies of women and men alone.

As we found some evidence to suggest that the women-to-men RRRs tended to be smaller in studies of lower quality (Fig. 4 and ESM Fig. 4), our results may underestimate any true sex difference. A significant degree of heterogeneity was also observed between studies conducted in and outside Asia with regards to all-site cancer mortality (ESM Fig. 19). However, we did not find heterogeneity between regions for our primary outcome, nor for the other secondary outcomes (all-site cancer incidence), and thus we speculate that this may be a chance finding consequent to the high number of statistical tests conducted.

Although we found a slightly higher women-to-men RRR for cancer incidence than cancer mortality, the finding may be explained by chance differences between the included studies, as almost identical pooled RRR estimates were obtained in the sensitivity analysis restricted to five studies which provided the sex-specific RRs for both incidence and mortality from the same study.

With regard to cancer at specific sites, previous meta-analyses have yielded inconsistent results of increased (stomach, lung, kidney), similar (oesophagus, colorectum, pancreas, bladder, thyroid) or decreased (liver) excess risk of cancer associated with diabetes in women compared with men. However, unlike our methods, these analyses included single-sex studies as well as studies among both women and men.

There are several possible explanations for the excess risk of cancer conferred by diabetes in women than men. One possible mechanism is poor glycaemic control in women with diabetes compared with men with diabetes. Hyperglycaemia may have carcinogenic effects by causing DNA damage, which could result from increased oxidative stress due to hyperglycaemia or from hyperglycaemia itself. Historically, women were likely to be undertreated or receive less intensive care compared with men. Further, a recent study showed that adherence to glucose-lowering medication was lower in women than men. As such, the carcinogenic effects of hyperglycaemia may be enhanced in women and subsequently lead to an increased cancer risk compared with men. Alternatively, cumulative exposure to insulin resistance and subsequent hyperinsulinaemia may be longer in women compared with men. The average duration of impaired glucose tolerance or impaired fasting glucose has been found to be more than 2 years longer in women than men, suggesting that women may have more exposure to, often untreated, hyperinsulinaemia in the prediabetic state. Hyperinsulinaemia promotes cancer cell proliferation by stimulating the insulin receptor directly and insulin-like growth factor-1 indirectly. Another factor that may, to some extent, explain the smaller RR for incidence of all-site cancer in men compared with women is the apparent protective effect of diabetes on prostate cancer in men with diabetes. Sex-specific cancers or site-specific cancers in which diabetes conferred greater or lower excess risk in women than men may also account for the association, although the degree of contribution cannot be determined from our analyses. In addition to sex difference for all-site cancer, we found also that diabetes conferred a significantly greater RR in women than men for oral, stomach and kidney cancer and for leukaemia, but a lower RR for liver cancer. The underlying mechanisms for sex differences in each specific association are not clear. However, unmeasured confounding factors specific to each site, such as Helicobacter pylori infection for stomach cancer and hepatitis virus infection for liver cancer, might be involved. However, the literature around mechanisms underpinning the sex differences in site-specific cancers is scant and further studies are required to confirm and clarify these sex differences in site-specific associations. Finally, the studies in our analyses were not adjusted for female-specific factors including pregnancy, menopausal status and use of hormone replacement therapy that have also been associated with diabetes and cancer.

We quantified sex differences based on RRs rather than risk differences. This might introduce a statistical artefact, in which the generally higher absolute risk for cancer in men, and the same risk difference subsequent to diabetes in each sex, would translate to a greater relative risk in women than men. However, this would require that risks of cancers associated with diabetes are additive rather than multiplicative, which is not generally considered to be the case in epidemiology. Indeed, RRs are much more commonly reported than risk differences in both epidemiological studies and clinical trials. Also, unlike risk differences, RRs are typically fairly stable across populations with different background risks, which make them suitable for summarisation of effects in meta-analyses. Furthermore, our previous meta-analyses on risk factors for cardiovascular diseases demonstrated that detection of a female disadvantage in RRs is not inevitable when men have higher absolute risk. We thus believe that the use of RRs in the present analyses is both practical and justifiable.

The strengths of this meta-analysis are its size and the inclusion of studies on the sex-specific effects of diabetes on all-site cancer and 50 site-specific cancers, which enabled us to conduct the most comprehensive analyses to date on the sex-specific effects of diabetes on cancer risk. To limit the risk of bias, we only included cohort studies that were conducted in men and women and had adjusted for at least age. Limitations of this study are inherent to the use of published data and the heterogeneity between studies in ascertainment of diabetes, study design and duration, endpoint definition and degree of adjustment for confounders. Nevertheless, a range of subgroup analysis provided broadly consistent results. However, as we compared women and men from within the same study, any effect of differences in methods between studies is likely to have affected women and men similarly. We therefore assume that the sex comparisons reported in this analysis are still valid. Second, the lack of data on duration of diabetes and the degree of glycaemic control precluded more detailed analyses on the effect of diabetes on the risk of cancer. Third, as this meta-analysis largely used published data, endpoint definition varied across the studies. Fourth, in analysis of all-site cancer, the women-to-men RRRs depend not only on the strengths of the RRRs of site-specific cancers (as illustrated by Fig. 5), but also on the relative incidence of site-specific cancers, which varies considerably between populations. This is likely to be a key factor in the high between-study heterogeneity we show in Fig. 3. Finally, studies generally did not adjust for obstetric and gynaecological history and unmeasured confounding is likely in the current estimates. However, confounding is likely to have been non-differentially distributed between women and men from the same study and we therefore assume that it had only a negligible effect on the reported associations.

In conclusion, diabetes is a risk factor for all-site cancer in both sexes, with a stronger effect in women than men. Sex differences varied across the location of the cancer, heightening the importance of a sex-specific approach to quantification of the role of diabetes in cancer research, prevention and treatment. Further studies are needed to clarify the mechanisms underlying the sex differences in the diabetes–cancer association.

References 142

  1. 1.
    Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 · 2016
    Corrected
  2. 2.

    Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524-548.

    Not in our library10.1001/jamaoncol.2016.5688

  3. 3.

    International Diabetes Federation (2015) IDF Diabetes Atlas, 7th edn. IDF, Brussels. Available from https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventhedition.html. Accessed 12 May 2018

    Not in our library

  4. 4.

    Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17:616-628.

    Not in our library10.4158/ep10357.ra

  5. 5.

    Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011;23:1127-1135.

    Not in our library10.1097/meg.0b013e32834b8d73

  6. 6.

    Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49:2411-2423.

    Not in our library10.1016/j.ejca.2013.02.025

  7. 7.

    Bao C, Yang X, Xu W, et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J Diabetes Complicat. 2013;27:357-364.

    Not in our library10.1016/j.jdiacomp.2013.01.004

  8. 8.

    Huang W, Ren H, Ben Q, Cai Q, Zhu W, Li Z. Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies. Cancer Causes Control. 2012;23:263-272.

    Not in our library10.1007/s10552-011-9874-9

  9. 9.

    Kramer HU, Schottker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer. 2012;48:1269-1282.

    Not in our library10.1016/j.ejca.2011.07.010

  10. 10.

    Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928-1937.

    Not in our library10.1016/j.ejca.2011.03.003

  11. 11.

    Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer. 2013;13:310.

    Not in our library10.1186/1471-2407-13-310

  12. 12.

    Schmid D, Behrens G, Jochem C, Keimling M, Leitzmann M. Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis. Eur J Epidemiol. 2013;28:945-958.

    Not in our library10.1007/s10654-013-9865-0

  13. 13.

    Wang Y, Wang B, Yan S, et al. Type 2 diabetes and gender differences in liver cancer by considering different confounding factors: a meta-analysis of cohort studies. Ann Epidemiol. 2016;26:764-772.

    Not in our library10.1016/j.annepidem.2016.09.006

  14. 14.

    Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.

    Not in our library10.1136/bmj.g7607

  15. 15.

    Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014;383:1973-1980.

    Not in our library10.1016/s0140-6736(14)60040-4

  16. 16.

    Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57:1542-1551.

    Not in our library10.1007/s00125-014-3260-6

  17. 17.

    Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39:300-307.

    Not in our library10.2337/dc15-1588

  18. 18.

    Lam EK, Batty GD, Huxley RR, et al. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol. 2011;22:730-738.

    Not in our library10.1093/annonc/mdq405

  19. 19.

    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Not in our library10.1136/bmj.b2535

  20. 20.

    Wells G, Shea B, O’Connell D et al. (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 17 Jun 2017

    Not in our library

  21. 21.

    Ragozzino M, Melton IIILJ, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35:13-19.

    Not in our library10.1016/0021-9681(82)90025-x

  22. 22.

    Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104:1499-1507.

    Not in our library10.1111/cas.12241

  23. 23.

    Gini A, Bidoli E, Zanier L, et al. Cancer among patients with type 2 diabetes mellitus: a population-based cohort study in northeastern Italy. Cancer Epidemiol. 2016;41:80-87.

    Not in our library10.1016/j.canep.2016.01.011

  24. 24.

    Berger SM, Gislason G, Moore LL, et al. Associations between metabolic disorders and risk of cancer in Danish men and women—a nationwide cohort study. BMC Cancer. 2016;16:133.

    Not in our library10.1186/s12885-016-2122-7

  25. 25.
    Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals · 2016
    No notice
  26. 26.

    Hense HW, Kajuter H, Wellmann J, Batzler WU. Cancer incidence in type 2 diabetes patients—first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr. 2011;3:15.

    Not in our library10.1186/1758-5996-3-15

  27. 27.

    Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49:945-952.

    Not in our library10.1007/s00125-006-0207-6

  28. 28.

    Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194-202.

    Not in our library10.1001/jama.293.2.194

  29. 29.

    Wang M, Hu RY, Wu HB, et al. Cancer risk among patients with type 2 diabetes mellitus: a population-based prospective study in China. Sci Rep. 2015;5:11503.

    Not in our library10.1038/srep11503

  30. 30.

    Hsu PC, Lin WH, Kuo TH, Lee HM, Kuo C, Li CY. A population-based cohort study of all-cause and site-specific cancer incidence among patients with type 1 diabetes mellitus in Taiwan. J Epidemiol. 2015;25:567-573.

    Not in our library10.2188/jea.je20140197

  31. 31.

    Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307-314.

    Not in our library10.1007/bf00051670

  32. 32.

    Dankner R, Boffetta P, Balicer RD, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183:1098-1106.

    Not in our library10.1093/aje/kwv290

  33. 33.

    Lai GY, Park Y, Hartge P, Hollenbeck AR, Freedman ND. The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. J Clin Endocrinol Metab. 2013;98:E497-E502.

    Not in our library10.1210/jc.2012-3335

  34. 34.

    Xu HL, Fang H, Xu WH, et al. Cancer incidence in patients with type 2 diabetes mellitus: a population-based cohort study in Shanghai. BMC Cancer. 2015;15:852.

    Not in our library10.1186/s12885-015-1887-4

  35. 35.

    Oberaigner W, Ebenbichler C, Oberaigner K, Juchum M, Schonherr HR, Lechleitner M. Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC Public Health. 2014;14:1058.

    Not in our library10.1186/1471-2458-14-1058

  36. 36.

    Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38:264-270.

    Not in our library10.2337/dc14-1996

  37. 37.

    Walker JJ, Brewster DH, Colhoun HM, et al. Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001-2007. Diabetologia. 2013;56:1712-1715.

    Not in our library10.1007/s00125-013-2937-6

  38. 38.

    Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control. 2010;21:879-887.

    Not in our library10.1007/s10552-010-9515-8

  39. 39.

    Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL. A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care. 2012;35:113-118.

    Not in our library10.2337/dc11-0255

  40. 40.

    Zhang PH, Chen ZW, Lv D, et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health. 2012;12:567.

    Not in our library10.1186/1471-2458-12-567

  41. 41.

    Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30:561-567.

    Not in our library10.2337/dc06-0922

  42. 42.

    Joshu CE, Prizment AE, Dluzniewski PJ, et al. Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. Int J Cancer. 2012;131:1667-1677.

    Not in our library10.1002/ijc.27394

  43. 43.

    Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360-1365.

    Not in our library10.1093/jnci/89.18.1360

  44. 44.

    Bancks MP, Odegaard AO, Pankow JS, et al. Glycated hemoglobin and all-cause and cause-specific mortality in Singaporean Chinese without diagnosed diabetes: the Singapore Chinese Health Study. Diabetes Care. 2014;37:3180-3187.

    Not in our library10.2337/dc14-0390

  45. 45.

    Guzder RN, Gatling W, Mullee MA, Byrne CD. Early mortality from the time of diagnosis of type 2 diabetes: a 5-year prospective cohort study with a local age- and sex-matched comparison cohort. Diabet Med. 2007;24:1164-1167.

    Not in our library10.1111/j.1464-5491.2007.02223.x

  46. 46.

    Morimoto A, Onda Y, Nishimura R, Sano H, Utsunomiya K, Tajima N. Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up: the DERI Mortality Study. Diabetologia. 2013;56:2171-2175.

    Not in our library10.1007/s00125-013-3001-2

  47. 47.

    Swerdlow AJ, Laing SP, Dos Santos Silva I, et al. Mortality of South Asian patients with insulin-treated diabetes mellitus in the United Kingdom: a cohort study. Diabet Med. 2004;21:845-851.

    Not in our library10.1111/j.1464-5491.2004.01253.x

  48. 48.

    Kato M, Noda M, Mizoue T, et al. Diagnosed diabetes and premature death among middle-aged Japanese: results from a large-scale population-based cohort study in Japan (JPHC study). BMJ Open. 2015;5:e007736.

    Not in our library10.1136/bmjopen-2015-007736

  49. 49.

    Baena-Diez JM, Penafiel J, Subirana I, et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 2016;39:1987-1995.

    Not in our library10.2337/dc16-0614

  50. 50.

    Kang YM, Kim YJ, Park JY, Lee WJ, Jung CH. Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013. Cardiovasc Diabetol. 2016;15:131.

    Not in our library10.1186/s12933-016-0451-0

  51. 51.

    Zhou XH, Qiao Q, Zethelius B, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867-1876.

    Not in our library10.1007/s00125-010-1796-7

  52. 52.

    Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27:1605-1609.

    Not in our library10.2337/diacare.27.7.1605

  53. 53.

    Gnavi R, Petrelli A, Demaria M, Spadea T, Carta Q, Costa G. Mortality and educational level among diabetic and non-diabetic population in the Turin Longitudinal Study: a 9-year follow-up. Int J Epidemiol. 2004;33:864-871.

    Not in our library10.1093/ije/dyh089

  54. 54.

    Hirakawa Y, Ninomiya T, Mukai N, et al. Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. Am J Epidemiol. 2012;176:856-864.

    Not in our library10.1093/aje/kws178

  55. 55.

    Forssas E, Sund R, Manderbacka K, Arffman M, Ilanne-Parikka P, Keskimaki I. Increased cancer mortality in diabetic people treated with insulin: a register-based follow-up study. BMC Health Serv Res. 2013;13:267.

    Not in our library10.1186/1472-6963-13-267

  56. 56.

    Fedeli U, Zoppini G, Gennaro N, Saugo M. Diabetes and cancer mortality: a multifaceted association. Diabetes Res Clin Pract. 2014;106:e86-e89.

    Not in our library10.1016/j.diabres.2014.09.027

  57. 57.

    Gordon-Dseagu VL, Shelton N, Mindell J. Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the Health Survey for England and Scottish Health Survey cohorts. J Diabetes Complicat. 2014;28:791-797.

    Not in our library10.1016/j.jdiacomp.2014.06.016

  58. 58.

    Shen C, Schooling CM, Chan WM, Lee SY, Leung GM, Lam TH. Self-reported diabetes and mortality in a prospective Chinese elderly cohort study in Hong Kong. Prev Med. 2014;64:20-26.

    Not in our library10.1016/j.ypmed.2014.03.021

  59. 59.

    Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS, Ekbom A. Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. J Clin Epidemiol. 2001;54:802-809.

    Not in our library10.1016/s0895-4356(01)00342-0

  60. 60.

    Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35:1835-1844.

    Not in our library10.2337/dc12-0002

  61. 61.

    Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care. 2003;26:1047-1051.

    Not in our library10.2337/diacare.26.4.1047

  62. 62.

    Sievers ML, Nelson RG, Knowler WC, Bennett PH. Impact of NIDDM on mortality and causes of death in Pima Indians. Diabetes Care. 1992;15:1541-1549.

    Not in our library10.2337/diacare.15.11.1541

  63. 63.

    Romon I, Rey G, Mandereau-Bruno L, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes—the 2001-2006 ENTRED cohort. Diabet Med. 2014;31:946-953.

    Not in our library10.1111/dme.12435

  64. 64.

    Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59:3216-3222.

    Not in our library10.2337/db10-0862

  65. 65.

    Tierney EF, Geiss LS, Engelgau MM, et al. Population-based estimates of mortality associated with diabetes: use of a death certificate check box in North Dakota. Am J Public Health. 2001;91:84-92.

    Not in our library10.2105/ajph.91.1.84

  66. 66.

    Wong JS, Pearson DW, Murchison LE, Williams MJ, Narayan V. Mortality in diabetes mellitus: experience of a geographically defined population. Diabet Med. 1991;8:135-139.

    Not in our library10.1111/j.1464-5491.1991.tb01559.x

  67. 67.

    Bruno G, Merletti F, Boffetta P, et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Diabetologia. 1999;42:297-301.

    Not in our library10.1007/s001250051154

  68. 68.

    Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia. 1999;42:1050-1054.

    Not in our library10.1007/s001250051269

  69. 69.

    Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-1162.

    Not in our library10.2105/ajph.81.9.1158

  70. 70.

    Oba S, Nagata C, Nakamura K, Takatsuka N, Shimizu H. Self-reported diabetes mellitus and risk of mortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based prospective cohort study in Japan. J Epidemiol. 2008;18:197-203.

    Not in our library10.2188/jea.je2008004

  71. 71.

    Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol. 1990;131:254-262.

    Not in our library10.1093/oxfordjournals.aje.a115495

  72. 72.

    Idilbi NM, Barchana M, Milman U, Carel RS. Incidence of cancer among diabetic and non-diabetic adult Israeli Arabs. Isr Med Assoc J. 2013;15:342-347.

    Not in our library

  73. 73.

    Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open. 2015;5:e007825.

    Not in our library10.1136/bmjopen-2015-007825

  74. 74.

    Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med. 2010;27:791-797.

    Not in our library10.1111/j.1464-5491.2010.03011.x

  75. 75.

    Lin CC, Chiang JH, Li CI, et al. Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan. BMC Cancer. 2014;14:381.

    Not in our library10.1186/1471-2407-14-381

  76. 76.

    Xu HL, Tan YT, Epplein M, et al. Population-based cohort studies of type 2 diabetes and stomach cancer risk in Chinese men and women. Cancer Sci. 2015;106:294-298.

    Not in our library10.1111/cas.12597

  77. 77.

    Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomark Prev. 2004;13:915-919.

    Not in our library

  78. 78.

    Limburg PJ, Vierkant RA, Fredericksen ZS, et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol. 2006;101:1872-1879.

    Not in our library10.1111/j.1572-0241.2006.00725.x

  79. 79.

    Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147-1154.

    Not in our library10.1093/jnci/91.13.1147

  80. 80.

    Campbell PT, Deka A, Jacobs EJ, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology. 2010;139:1138-1146.

    Not in our library10.1053/j.gastro.2010.06.072

  81. 81.

    Goto A, Noda M, Sawada N, et al. High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. Int J Cancer. 2016;138:1741-1753.

    Not in our library10.1002/ijc.29917

  82. 82.

    Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol. 1998;147:816-825.

    Not in our library10.1093/oxfordjournals.aje.a009534

  83. 83.

    Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst. 2006;98:135-138.

    Not in our library10.1093/jnci/djj015

  84. 84.

    Magliano DJ, Davis WA, Shaw JE, Bruce DG, Davis TM. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol. 2012;167:589-599.

    Not in our library10.1530/eje-12-0053

  85. 85.

    Jarvandi S, Davidson NO, Schootman M. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. PLoS One. 2013;8:e74616.

    Not in our library10.1371/journal.pone.0074616

  86. 86.

    Sikdar KC, Walsh SJ, Roche M, Jiang Y, Syrowatka A, Collins KD. Diabetes and sex-specific colorectal cancer risks in Newfoundland and Labrador: a population-based retrospective cohort study. Can J Public Health. 2013;104:e101-e107.

    Not in our library10.1007/bf03405668

  87. 87.

    He J, Stram DO, Kolonel LN, Henderson BE, Le Marchand L, Haiman CA. The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. Br J Cancer. 2010;103:120-126.

    Not in our library10.1038/sj.bjc.6605721

  88. 88.

    de Kort S, Simons CC, van den Brandt PA, et al. Diabetes mellitus type 2 and subsite-specific colorectal cancer risk in men and women: results from the Netherlands Cohort Study on diet and cancer. Eur J Gastroenterol Hepatol. 2016;28:896-903.

    Not in our library10.1097/meg.0000000000000626

  89. 89.
    Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis · 2001
    No notice
  90. 90.

    Koskinen SV, Reunanen AR, Martelin TP, Valkonen T. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health. 1998;88:765-770.

    Not in our library10.2105/ajph.88.5.765

  91. 91.

    Tan C, Mori M, Adachi Y, et al. Diabetes mellitus and risk of colorectal Cancer mortality in Japan: the Japan Collaborative Cohort Study. Asian Pac J Cancer Prev. 2016;17:4681-4688.

    Not in our library10.22034/apjcp.2016.17.10.4681

  92. 92.

    Ren X, Zhang X, Zhang X, et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health. 2009;123:540-544.

    Not in our library10.1016/j.puhe.2009.06.019

  93. 93.

    Chen HF, Chen P, Su YH, Su HF, Li CY. Age- and sex-specific risks of colorectal cancers in diabetic patients. Tohoku J Exp Med. 2012;226:259-265.

    Not in our library10.1620/tjem.226.259

  94. 94.

    Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst. 1997;89:660-661.

    Not in our library10.1093/jnci/89.9.660

  95. 95.

    Onitilo AA, Berg RL, Engel JM, et al. Increased risk of colon cancer in men in the pre-diabetes phase. PLoS One. 2013;8:e70426.

    Not in our library10.1371/journal.pone.0070426

  96. 96.

    Adami HO, Chow WH, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472-1477.

    Not in our library10.1093/jnci/88.20.1472

  97. 97.

    Campbell PT, Newton CC, Freedman ND, et al. Body mass index, waist circumference, diabetes, and risk of liver Cancer for U.S. adults. Cancer Res. 2016;76:6076-6083.

    Not in our library10.1158/0008-5472.can-16-0787

  98. 98.

    Yang WS, Shu XO, Gao J, et al. Prospective evaluation of type 2 diabetes mellitus on the risk of primary liver cancer in Chinese men and women. Ann Oncol. 2013;24:1679-1685.

    Not in our library10.1093/annonc/mdt017

  99. 99.

    Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182-1188.

    Not in our library10.1038/bjc.2013.25

  100. 100.

    Wild SH, Morling JR, McAllister DA, et al. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol. 2016;64:1358-1364.

    Not in our library10.1016/j.jhep.2016.01.014

  101. 101.

    Fujino Y, Mizoue T, Tokui N, Yoshimura T. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev. 2001;17:374-379.

    Not in our library10.1002/dmrr.214

  102. 102.

    Shibata A, Ogimoto I, Kurozawa Y, et al. Past medical history and risk of death due to hepatocellular carcinoma, univariate analysis of JACC study data. Kurume Med J. 2003;50:109-119.

    Not in our library10.2739/kurumemedj.50.109

  103. 103.

    Chiang CH, Lee LT, Hung SH, et al. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology. 2014;59:2207-2215.

    Not in our library10.1002/hep.27014

  104. 104.

    Chen HF, Chen P, Li CY. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. Hepatology. 2010;52:155-163.

    Not in our library10.1002/hep.23641

  105. 105.

    Yagyu K, Lin Y, Obata Y, et al. Bowel movement frequency, medical history and the risk of gallbladder cancer death: a cohort study in Japan. Cancer Sci. 2004;95:674-678.

    Not in our library10.1111/j.1349-7006.2004.tb03328.x

  106. 106.

    Tsai MS, Lee PH, Lin CL, Peng CL, Kao CH. Type II diabetes mellitus is associated with a reduced risk of cholangiocarcinoma in patients with biliary tract diseases. Int J Cancer. 2015;136:2409-2417.

    Not in our library10.1002/ijc.29292

  107. 107.
    Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts · 2005
    No notice
  108. 108.

    Nilsen TI, Vatten LJ. A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag, Norway. Cancer Causes Control. 2000;11:645-652.

    Not in our library10.1023/a:1008916123357

  109. 109.

    Chow WH, Gridley G, Nyren O, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst. 1995;87:930-931.

    Not in our library10.1093/jnci/87.12.930

  110. 110.

    Lin Y, Tamakoshi A, Kawamura T, et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer. 2002;99:742-746.

    Not in our library10.1002/ijc.10402

  111. 111.

    Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28:590-594.

    Not in our library10.2337/diacare.28.3.590

  112. 112.

    Yang WS, Yang Y, Yang G, et al. Pre-existing type 2 diabetes and risk of lung cancer: a report from two prospective cohort studies of 133 024 Chinese adults in urban Shanghai. BMJ Open. 2014;4:e004875.

    Not in our library10.1136/bmjopen-2014-004875

  113. 113.

    Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the Multiethnic Cohort. Am J Epidemiol. 2007;166:932-940.

    Not in our library10.1093/aje/kwm170

  114. 114.

    Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia. 1999;42:107-112.

    Not in our library10.1007/s001250051122

  115. 115.

    Washio M, Mori M, Khan M, et al. Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). Int J Urol. 2007;14:393-397.

    Not in our library10.1111/j.1442-2042.2007.01744.x

  116. 116.

    Goossens ME, Zeegers MP, Bazelier MT, De Bruin ML, Buntinx F, de Vries F. Risk of bladder cancer in patients with diabetes: a retrospective cohort study. BMJ Open. 2015;5:e007470.

    Not in our library10.1136/bmjopen-2014-007470

  117. 117.

    Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer. 2013;132:2186-2191.

    Not in our library10.1002/ijc.27878

  118. 118.

    Woolcott CG, Maskarinec G, Haiman CA, Henderson BE, Kolonel LN. Diabetes and urothelial cancer risk: the Multiethnic Cohort study. Cancer Epidemiol. 2011;35:551-554.

    Not in our library10.1016/j.canep.2011.02.014

  119. 119.

    Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871-1877.

    Not in our library10.1001/archinte.166.17.1871

  120. 120.

    Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev. 2006;7:253-259.

    Not in our library

  121. 121.

    Khan AE, Gallo V, Linseisen J, et al. Diabetes and the risk of non-Hodgkin’s lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica. 2008;93:842-850.

    Not in our library10.3324/haematol.12297

  122. 122.

    Yang WS, Li HL, Xu HL, et al. Type 2 diabetes and the risk of non-Hodgkin’s lymphoma: a report from two population-based cohort studies in China. Eur J Cancer Prev. 2016;25:149-154.

    Not in our library10.1097/cej.0000000000000150

  123. 123.

    Erber E, Lim U, Maskarinec G, Kolonel LN. Common immune-related risk factors and incident non-Hodgkin lymphoma: the Multiethnic Cohort. Int J Cancer. 2009;125:1440-1445.

    Not in our library10.1002/ijc.24456

  124. 124.

    Weiderpass E, Gridley G, Ekbom A, Nyren O, Hjalgrim H, Adami HO. Medical history risk factors for non-Hodgkin’s lymphoma in older women. J Natl Cancer Inst. 1997;89:816-817.

    Not in our library10.1093/jnci/89.11.816

  125. 125.

    Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer. 1997;71:360-363.

    Not in our library10.1002/(sici)1097-0215(19970502)71:3<360::aid-ijc9>3.0.co;2-w

  126. 126.

    Kitahara CM, Platz EA, Beane Freeman LE, et al. Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies. Cancer Causes Control. 2012;23:463-471.

    Not in our library10.1007/s10552-012-9896-y

  127. 127.

    Hemminki K, Forsti A, Sundquist K, Li X. Cancer of unknown primary is associated with diabetes. Eur J Cancer Prev. 2016;25:246-251.

    Not in our library10.1097/cej.0000000000000165

  128. 128.

    Kautzky-Willer A, Kamyar MR, Gerhat D, et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend Med. 2010;7:571-583.

    Not in our library10.1016/j.genm.2010.12.001

  129. 129.

    Petitti DB, Klingensmith GJ, Bell RA, et al. Glycemic control in youth with diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr. 2009;155:668-672.e661-663.

    Not in our library10.1016/j.jpeds.2009.05.025

  130. 130.

    Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des. 2008;14:940-945.

    Not in our library10.2174/138161208784139765

  131. 131.

    Lorenzi M, Montisano DF, Toledo S, Barrieux A. High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest. 1986;77:322-325.

    Not in our library10.1172/jci112295

  132. 132.

    Kramer HU, Raum E, Ruter G, et al. Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. Cardiovasc Diabetol. 2012;11:88.

    Not in our library10.1186/1475-2840-11-88

  133. 133.

    Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38:604-609.

    Not in our library10.2337/dc14-2098

  134. 134.

    Bertram MY, Vos T. Quantifying the duration of pre-diabetes. Aust N Z J Public Health. 2010;34:311-314.

    Not in our library10.1111/j.1753-6405.2010.00532.x

  135. 135.

    Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685.

    Not in our library10.2337/dc10-0666

  136. 136.

    Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151-158.

    Not in our library10.1038/pcan.2012.40

  137. 137.

    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789.

    Not in our library10.1056/nejmoa001999

  138. 138.

    Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-1801.

    Not in our library10.1056/nejm199306243282501

  139. 139.

    Szmuilowicz ED, Stuenkel CA, Seely EW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol. 2009;5:553-558.

    Not in our library10.1038/nrendo.2009.166

  140. 140.

    Shapiro S. Recent epidemiological evidence relevant to the clinical management of the menopause. Climacteric. 2007;10(Suppl 2):2-15.

    Not in our library10.1080/13697130701606754

  141. 141.

    Peters SA, Huxley RR, Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke. 2013;44:2394-2401.

    Not in our library10.1161/strokeaha.113.001624

  142. 142.

    Mongraw-Chaffin ML, Peters SA, Huxley RR, Woodward M. The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1.2 million participants. Lancet Diabetes Endocrinol. 2015;3:437-449.

    Not in our library10.1016/s2213-8587(15)00086-8

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.